For a large pharmaceutical company, an IMP (Investigational Medicinal Product) Quality Manager is sought to ensure GMP compliance and quality of investigational products.
Typical responsibilities in this role:
- Review and approval of manufacturing and batch protocols (Batch Records) for drug substance and drug product.
- Execution of final quality release of investigational products for use in clinical trials.
- Review and approval of GMP-relevant documents such as SOPs, validation reports, deviations and change control requests.
- Creation and maintenance of product-specific quality agreements with internal and external partners.
- Support for production and QC departments on all GMP-related questions and quality issues.
- Planning and conducting internal audits and support during regulatory inspections and external audits.
- Management and oversight of CAPA (Corrective and Preventive Actions) measures for sustainable problem resolution.
Relevant technologies, tools or methods:
- Quality management systems (QMS): Veeva Vault QMS, MasterControl, TrackWise, SAP QM.
- Document Management Systems (DMS): Veeva Vault, OpenText Documentum.
- ERP systems: SAP S/4HANA (especially QM module).
- Laboratory Information Management Systems (LIMS).
- Manufacturing Execution Systems (MES).
- Methods: risk analysis (FMEA), root cause analysis (5 Whys, Ishikawa), statistical process control (SPC).
Typical KPIs or success metrics:
- Batch Release Time: average time from production completion to final release (target: < X days).
- Right-First-Time Rate: percentage of batches released without deviations or rework (target: > 95%).
- CAPA Effectiveness: reduction in recurrence rate of deviations after CAPA implementation (target: > 80%).
- Audit Performance: number of critical/major findings in internal and external audits (target: 0).
- Deviation Closure Rate: percentage of deviations closed within the defined timeframe (target: > 90%).
Key challenges, risks or specifics:
- High complexity and variability due to the development of new molecules and processes in the clinical phase.
- Strict adherence to constantly evolving GMP regulations (e.g. EU Annex 1 for sterile products).
- Ensuring product quality and patient safety under high time pressure (time-to-market).
- Managing interfaces between development, manufacturing, QC, and regulatory affairs.
- Risk of supply chain interruptions for critical raw materials or services.
- Ensuring data integrity in all quality-relevant systems.
Concrete deliverables:
- Released batches of investigational products.
- Approved master batch records and SOPs.
- Completed and assessed deviation and change reports.
- Audit and inspection reports with tracked action plans.
- Valid quality agreements with all relevant partners.
- Regular quality reports for management.